Why this page has no before-and-after photos
Photos answer the wrong question. The people who post them are the ones whose results were worth posting — that is selection bias, not evidence, and no photo tells you whether you would get the same. What you actually want to know is how much people lose on average, how many hit each level, and how long it takes. Those numbers exist, from trials with thousands of participants, and they are on this page instead.
What Ozempic actually produced in its trial
Ozempic is not approved for weight loss. There is no published responder distribution for Ozempic — SUSTAIN is a blood-sugar programme, not a weight programme. Any page showing you "% who lost 10% on Ozempic" is quoting Wegovy trial data under the wrong drug name. Most dramatic "Ozempic before and after" results you see online are either off-label use in people without diabetes, Wegovy results mislabelled, or compounded semaglutide.
Ozempic is not approved for weight loss, and its trials never measured it as a primary outcome. Where weight was tracked as a secondary endpoint, semaglutide 2 mg produced about 6.9 kg over 40 weeks — roughly half what the weight-loss dose in Wegovy produces.
SUSTAIN FORTE / SUSTAIN 7 · 40 weeks · adults with type 2 diabetes
−6.9 kg at 2 mg over 40 weeks (secondary endpoint, SUSTAIN FORTE); −6.5 kg at 1 mg over 40 weeks (SUSTAIN 7)
SUSTAIN programme — weight was a secondary endpoint (n varies by trial)
Why you will not find a “% who lost 10%” figure for Ozempic
There is no published responder distribution for Ozempic — SUSTAIN is a blood-sugar programme, not a weight programme. Any page showing you "% who lost 10% on Ozempic" is quoting Wegovy trial data under the wrong drug name. Most dramatic "Ozempic before and after" results you see online are either off-label use in people without diabetes, Wegovy results mislabelled, or compounded semaglutide.
Why "Ozempic results" are usually someone else’s drug
Ozempic is semaglutide capped at 2 mg and approved for type 2 diabetes. Wegovy is the same molecule at 2.4 mg, approved for weight. The gap between them is not marginal: about −6.9 kg over 40 weeks at the Ozempic ceiling versus −14.9% of body weight over 68 weeks in the Wegovy trial. When a transformation is captioned "Ozempic", it is usually one of three things — off-label use in someone without diabetes, a Wegovy result relabelled, or compounded semaglutide.
There is a second reason the numbers look smaller here. Ozempic is prescribed to people with type 2 diabetes, and diabetes independently blunts GLP-1 weight loss by roughly a third. So an Ozempic patient is usually taking a lower dose AND sitting in the population that responds least. Both effects point the same way.
The timeline: when each change actually happens
Neither pivotal trial publishes a week-by-week table — they publish a curve — so anyone quoting you a precise “week 8 average” is inventing it. These are the points that are actually published, and they are enough to set expectations honestly.
Both drugs start below the therapeutic dose — semaglutide at 0.25 mg, tirzepatide at 2.5 mg — specifically to let the gut adjust. This month is about tolerating the drug, not losing weight, and expecting a dramatic change here is the most common reason people conclude it "is not working."
In a SURMOUNT-1 analysis, 82% of participants had reached at least 5% weight loss by week 12. The other 18% had not — and that is the number worth knowing, because it is not a verdict.
The 20-week run-in of STEP 4 took participants to −10.6% by the end of titration. Among the slower responders from week 12, 70% had crossed 5% by week 24.
The 36-week lead-in of SURMOUNT-4, at 10–15 mg, reached −20.9% — roughly eight months in.
STEP 1 plateaus around week 60 at −14.9%; SURMOUNT-1 reaches −20.9% by week 72. STEP 5 followed people to week 104 and found −15.2%, essentially unchanged — so after roughly 15 months the line is flat.
If your first month looks like nothing, read this before you quit
This is the single most useful finding for anyone comparing themselves to someone else's transformation. In a SURMOUNT-1 analysis, 82% of participants had lost at least 5% by week 12 — and 18% had not. Those slower responders were more likely to be male, heavier at baseline, and starting from a higher BMI. Here is what happened to them:
- By week 24, 70% of the slow group had crossed 5%.
- By week 72, 90% of them had.
- Their average time to reach 5% was about 25 weeks, not 12.
They did end up lower than the fast group — around 14.6% versus 23.3% at week 72 — so early response does predict something. But “slower” and “not working” are different things, and nine out of ten people in that group got to a clinically meaningful result by waiting rather than quitting.
The two things a before-and-after photo never shows you
1. What happens when you stop
This is the part missing from every transformation post. In the STEP 1 extension, participants who had reached −17.3% were followed for a year after stopping semaglutide entirely: they regained 11.6 percentage points, finishing at −5.6% — roughly two-thirds of the loss came back within a year. Most of the improvements in blood pressure and cholesterol drifted back towards baseline with it.
Tirzepatide behaves the same way. In SURMOUNT-4, people who stopped after reaching −20.9% regained 14.0%over the following year, while those who continued lost a further 5.5%. Nearly 90% of those who stayed on treatment kept at least 80% of what they had lost; only 16.6% of those who stopped did. These are maintenance drugs, and the “after” photo is a snapshot of a state that requires continuing to hold.
2. Some of it was not fat
Body-composition substudies using DXA scans found that roughly a quarter to a third of the weight lost is lean mass rather than fat — and importantly, that is the same proportion as losing weight without a drug. In the SURMOUNT-1 substudy about 75% of the loss was fat and 25% lean, identical to the placebo group. It is not a drug effect; it is what rapid weight loss does. It is also the reason protein intake and resistance training matter here — see our muscle-loss guide and protein targets.
What changes the number for you
- Whether you have type 2 diabetes. The single biggest modifier in the data. Same drug, same dose, same duration: semaglutide 2.4 mg gives −14.9% without diabetes and −9.6% with it; tirzepatide 15 mg gives −20.9% without and −14.7% with. Roughly a third of the effect.
- Which drug and which dose. Tirzepatide at 15 mg outperformed semaglutide 2.4 mg in the trial data, and both far outperform the diabetes-dose versions sold as Ozempic and Mounjaro.
- Whether you reach and stay on the maintenance dose. The titration months deliver less than the maintenance months; stopping early stops the curve early.
- Whether the product was ever studied. Compounded versions have no trials of their own. Every result figure quoted for them is borrowed from the branded trials.
Want the cross-drug view? The full GLP-1 weight-loss results comparison puts every drug's trial data side by side.